TOP - January 2021 Vol 14, No 1

The January issue of The Oncology Pharmacist (TOP) contains important news and updates for today’s oncology pharmacist, including highlights from recent national and international virtual conferences, exploring best practices in value-based performance in cancer care, strategies for providing high-quality and affordable care to patients during the COVID-19 pandemic, ongoing efforts to address social determinants of health and their effect on the delivery of healthcare, and the latest data on the safety and efficacy of novel agents and combination regimens for the treatment of patients with hematologic malignancies and solid tumors.
Total growth in the oncology pipeline in 2020 has been driven by targeted therapies, said Doug Long, Vice President, Industry Relations, IQVIA, at the 10th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2020.
The treatment of renal-cell carcinoma (RCC) continues to evolve with the development of more effective front-line regimens.
Myriad new treatment options have extended the survival and improved the quality of life for patients with cancer, but these options are also increasing the complexity of care.
Although chimeric antigen receptor (CAR) T-cell therapy has been a life-saving treatment for some patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), additional therapies may be able to perform equally well in select patients, said Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center, New York City, at the National Comprehensive Cancer Network 2020 Virtual Congress: hematologic malignancies.
At the National Comprehensive Cancer Network 2020 Virtual Congress: Hematalogic Malignancies, Shaji Kumar, MD, Consultant and Professor of Medicine, Division of Hematology, Mayo Clinic Cancer Center, Rochester, MN, discussed the “bonanza of treatment regimens for multiple myeloma.”
The approaches to the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma are evolving, including the sequencing of therapy and a possibly expanded role for minimal residual disease (MRD) status, said William G. Wierda, MD, PhD, Section Chief, Chronic Lymphocytic Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the National Comprehensive Cancer Network 2020 Virtual Congress: hematologic malignancies.
Although smoldering myeloma is acknowledged as a clinical entity, debate continues about whether to treat, when to treat, and how to treat this condition, said Natalie S. Callander, MD, Leader, Myeloma/Lymphoma Disease-Oriented Team, University of Wisconsin Carbone Cancer Center, Madison, at the National Comprehensive Cancer Network 2020 Virtual Congress: hematologic malignancies.
The COVID-19 pandemic has exposed many of the cracks in our healthcare system. According to Maurie Markman, MD, MS, FACP, FASCO, President, Medicine and Science, Cancer Treatment Centers of America, COVID-19 disproportionately affects the elderly, those with comorbidities, and racial and ethnic minority populations, all of whom are more likely to have serious or fatal illness.
n an environment of increasing vertical and horizontal integration in healthcare, are new value-based care models in oncology—such as the Centers for Medicare & Medicaid Services’ pilot payment project, the Oncology Care Model (OCM)—working? Five years from now, will we still be talking about efforts to go from volume to value using alternative payment models?
Page 1 of 2
Results 1 - 10 of 20